- Home
- PEN
PEN
Penumbra Inc.
as 05-30-2025 4:00pm EST
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 10.9B | IPO Year: | 2015 |
| Target Price: | $299.73 | AVG Volume (30 days): | 554.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.08 | EPS Growth: | -54.65 |
| 52 Week Low/High: | $148.00 - $310.00 | Next Earning Date: | 07-29-2025 |
| Revenue: | $1,240,100,000 | Revenue Growth: | 13.17% |
| Revenue Growth (this year): | 14.6% | Revenue Growth (next year): | 14.17% |
Stock Insider Trading Activity of Penumbra Inc. (PEN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| O'Rourke Bridget | PEN | Director | May 15 '25 | Sell | $286.15 | 100 | $28,615.00 | 5,423 | |
| Elsesser Adam | PEN | CEO and President | May 14 '25 | Sell | $296.28 | 16,600 | $4,950,475.83 | 90,437 | |
| Elsesser Adam | PEN | CEO and President | May 7 '25 | Sell | $290.94 | 16,650 | $4,818,006.32 | 90,437 | |
| Yuen Maggie | PEN | Chief Financial Officer | May 2 '25 | Sell | $299.01 | 2,000 | $598,020.00 | 13,957 | |
| Bose Arani | PEN | Director | Apr 25 '25 | Sell | $299.39 | 12,000 | $3,584,775.09 | 303,961 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Apr 24 '25 | Sell | $300.01 | 600 | $180,006.00 | 66,159 | |
| Elsesser Adam | PEN | CEO and President | Apr 16 '25 | Sell | $274.69 | 16,560 | $4,543,228.37 | 90,437 | |
| O'Rourke Bridget | PEN | Director | Apr 15 '25 | Sell | $271.21 | 50 | $13,560.50 | 5,423 | |
| Wilder Thomas | PEN | Director | Apr 2 '25 | Sell | $266.93 | 360 | $96,094.80 | 4,692 | |
| Elsesser Adam | PEN | CEO and President | Apr 2 '25 | Sell | $272.32 | 16,565 | $4,509,728.21 | 90,437 |
Latest Penumbra Inc. News
PEN Breaking Stock News: Dive into PEN Ticker-Specific Updates for Smart Investing
StockStory
3 days ago
Q1 Earnings Highs And Lows: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
Zacks
8 days ago
Why Is Penumbra (PEN) Down 10.6% Since Last Earnings Report?
Simply Wall St.
8 days ago
Penumbra (NYSE:PEN) shareholders are still up 88% over 3 years despite pulling back 3.1% in the past week
Zacks
9 days ago
Penumbra Rallies 35.9% in a Year: What's Driving the Stock?
PR Newswire
11 days ago
Penumbra, Inc. to Present at Upcoming Investor Conferences
StockStory
12 days ago
3 Healthcare Stocks Walking a Fine Line
StockStory
12 days ago
Reflecting On Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks’ Q1 Earnings: Merit Medical Systems (NASDAQ:MMSI)
Zacks
17 days ago
Here's Why Penumbra (PEN) is a Strong Growth Stock
Compare PEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PEN Penumbra Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.